The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

GSK is investing up to $800 million to double the size and capacity of its production site in Marietta, Pennsylvania, the company said Thursday. Through the addition of two new facilities ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment ...

GSK (GSK) plc announced what it calls its ... manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs, the company stated.

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

He is the brother of Yu Xue, who worked as a scientist at GSK in Pennsylvania and is one of four other people who have previously pleaded guilty to charges in connection with the case.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its ...